Back to search

Article

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

2020-08-07

Abstract excerpt

<h4>Summary</h4> Despite the genetic inactivation of SMARCA4 , a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. Thi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d838c376-33a0-5909-beb5-3b28209c425b
DOI
10.1101/2020.08.07.241232
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockadeDOI 10.1101/2020.08.07.241232
Select a neighboring publication to make it the new centre.